Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Read-GeneWAR:RDG 80 EBITDA Margin % is 25.58% as of Mar. 2026, which is 147% above its 10-year median of 10.34. GuruFocus rates WAR:RDG with a GF Score™ of 80/100 and a GF Value™ of zł6.37 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 940 Biotechnology companies, Read-Gene ranks better than 80.53% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Read-Gene's EBITDA for the
three
months ended in Mar. 2026 was zł1.00 Mil. Read-Gene's Revenue for the
three
months ended in Mar. 2026 was zł3.89 Mil. Therefore, Read-Gene's EBITDA margin for the quarter that ended in Mar. 2026 was 25.58%.
Read-Gene (WAR:RDG) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Read-Gene EBITDA Margin % Related Terms
Read-Gene EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Read-Gene's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:RDG vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Read-Gene's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Read-Gene EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Read-Gene's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Read-Gene's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Read-Gene (WAR:RDG) has a EBITDA Margin % of 25.58% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Read-Gene and its competitors. This is 147% above median its historical median of 10.34. According to the industry distribution chart, Read-Gene ranks #183 out of 940 companies in the Biotechnology industry, placing it in the top 19.5%.
Is Read-Gene's EBITDA Margin % too high?
Read-Gene's current EBITDA Margin % of 25.58% is 147% above median its 10-year median of 10.34. Based on the distribution chart, Read-Gene ranks #183 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Read-Gene has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Read-Gene's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Read-Gene ranks #183 out of 940 companies for EBITDA Margin %. This places Read-Gene in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Read-Gene and its competitors. Read-Gene's current EBITDA Margin % is 25.58%, which is 147% above median its own 10-year median of 10.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Read-Gene stock overvalued right now?
Based on GuruFocus' analysis, Read-Gene (WAR:RDG) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.37, compared to a current price of zł4.86 — trading 23.7% below its estimated fair value. The current EBITDA Margin % is 25.58%, which is 147% above median its 10-year median of 10.34. Read-Gene's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Read-Gene (WAR:RDG), the current EBITDA Margin % is 25.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Read-Gene (WAR:RDG) Overvalued in 2026?
Based on GuruFocus' analysis, Read-Gene stock appears to be undervalued.
The current stock price of zł4.86 is trading 23.7% below its estimated GF Value™ of zł6.37.
GuruFocus considers Read-Gene to be Modestly Undervalued.
Key valuation signals for WAR:RDG:
EBITDA Margin %: 25.58% (147% above median its 10-year median of 10.34)
GF Value™: zł6.37 vs. price of zł4.86 (23.7% below fair value)
No single metric tells the full story. See the WAR:RDG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
80GF Score
Get the complete analysis for WAR:RDG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:RDG has been successfully added to your 
